Unicycive Therapeutics, Inc. (UNCY): R&D Expense
$9.12M
Year ended 2025-12-31
$9.58M
Trailing 12 months to 2026-06-30
-9.8%
3-year compound annual growth
+55.1%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $9.12M | -54.4% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $20.01M | +55.1% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $12.90M | +3.7% | 2025-03-31, From 2023-01-01 |
| 2022-12-31 | $12.44M | +104.5% | 2024-03-28, From 2022-01-01 |
| 2021-12-31 | $6.08M | +499.0% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $1.01M | n/a | 2022-03-31, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | 2025-12-31 | $9.12M | -54.4% |
| Vistagen Therapeutics, Inc. (VTGN) | 2026-03-31 | $54.97M | +39.6% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $16.73M | +41.0% |
| NextCure, Inc. (NXTC) | 2025-12-31 | $44.92M | +8.3% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $30.81M | +14.8% |
| Akari Therapeutics Plc (AKTX) | 2025-12-31 | $2.81M | -59.7% |
| Atossa Therapeutics, Inc. (ATOS) | 2025-12-31 | $21.18M | +50.1% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $8.86M | -25.2% |
| Hyperion Defi, Inc. (HYPD) | 2025-12-31 | $1.91M | -86.8% |
Compare UNCY, VTGN, COYA, NXTC side by side · Screen every company in Pharmaceutical Preparations ↗